Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC01229 (long intergenic non-protein coding RNA 1229) is a lincRNA gene that encodes a long non-coding RNA transcript with no protein-coding potential[1][7]. It is expressed in several tissue types and has been experimentally shown to negatively regulate the transcription of the MAF gene, an important transcription factor in kidney and metabolic pathways[3][5]. LINC01229 is implicated in the regulation of serum urate levels and inflammation, making it relevant to the pathogenesis of diseases such as gout and potentially kidney disorders[3][5]. Its biological function appears to center on the modulation of gene expression networks rather than serving as a receptor or enzyme. Currently, LINC01229 is not a known direct therapeutic target, nor are there approved drugs designed to modulate its activity[1][3][5].
Not applicable for drugs, as this is a non-coding RNA. Mechanistically, LINC01229 represses expression of the MAF gene, possibly through chromatin/transcriptional interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1229 (LINC01229).